(Q38177849)

30 August 2017

The overlap between IBS and IBD: what is it and what does it mean? (English)

1 reference

30 August 2017

Vladimir Stanisic

1

1 reference

PubMed ID

24417262

30 August 2017

Eamonn M M Quigley

series ordinal

2

1 reference

30 August 2017

1 February 2014

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

1 reference

30 August 2017

8

1 reference

30 August 2017

139-145

1 reference

30 August 2017

2

1 reference

Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Genetics of the innate immune response in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Intestinal barrier function in health and gastrointestinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Intestinal permeability defects: is it time to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Mucosal cytokine imbalance in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Review article: monitoring the activity of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

Experiences of patients with chronic gastrointestinal conditions: in their own words

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876361

10.1586/17474124.2014.876361

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24417262